Published in Cancer Res on February 23, 2010
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ (2013) 1.60
Retracted Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res (2010) 0.95
Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment. Front Oncol (2011) 0.94
Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res (2012) 0.90
Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Res (2015) 0.84
Retracted Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs. Mol Cancer Ther (2012) 0.83
Metastatic melanoma - a review of current and future drugs. Drugs Context (2012) 0.83
The docking protein p130Cas regulates cell sensitivity to proteasome inhibition. BMC Biol (2011) 0.82
Strategies for enhancing vaccine-induced CTL antitumor immune responses. J Biomed Biotechnol (2012) 0.82
Reciprocal complementation of the tumoricidal effects of radiation and natural killer cells. PLoS One (2013) 0.82
Modulatory effects of bortezomib on host immune cell functions. Immunotherapy (2015) 0.80
Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes. Cancer Immun (2011) 0.79
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects. Am J Cancer Res (2011) 0.79
Systemic therapy of non-resectable metastatic melanoma. Cancers (Basel) (2010) 0.78
Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway. J Immunol (2014) 0.75
Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. Oncotarget (2016) 0.75
Noxa and cancer therapy: Tuning up the mitochondrial death machinery in response to chemotherapy. Mol Cell Oncol (2014) 0.75
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol (2011) 2.38
Role of aPKC isoforms and their binding partners Par3 and Par6 in epidermal barrier formation. J Invest Dermatol (2006) 1.91
T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology (2013) 1.77
Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J Invest Dermatol (2009) 1.75
Staphylococcus aureus subvert autophagy for induction of caspase-independent host cell death. J Biol Chem (2006) 1.73
Recent developments in adeno-associated virus vector technology. J Gene Med (2008) 1.66
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer (2010) 1.66
Riboflavin kinase couples TNF receptor 1 to NADPH oxidase. Nature (2009) 1.62
Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J Clin Invest (2006) 1.58
Identification and characterization of bacterial pathogens causing bloodstream infections by DNA microarray. J Clin Microbiol (2006) 1.55
A role for the human nucleotide-binding domain, leucine-rich repeat-containing family member NLRC5 in antiviral responses. J Biol Chem (2010) 1.55
Identification and discrimination of Staphylococcus aureus strains using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Proteomics (2002) 1.51
Merkel cell polyomavirus DNA in persons without merkel cell carcinoma. Emerg Infect Dis (2009) 1.45
Podoplanin expression in cutaneous head and neck squamous cell carcinoma--prognostic value and clinicopathologic implications. J Surg Oncol (2012) 1.44
Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol (2006) 1.43
[Patients' view of melanoma follow-up]. J Dtsch Dermatol Ges (2004) 1.43
Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother (2004) 1.43
Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. PLoS One (2011) 1.42
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol (2006) 1.41
IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res (2011) 1.33
Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein. J Biol Chem (2006) 1.32
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med (2012) 1.32
Molecular portraits of B cell lineage commitment. Proc Natl Acad Sci U S A (2002) 1.32
Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A (2011) 1.31
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27
Mechanical tension and integrin alpha 2 beta 1 regulate fibroblast functions. J Investig Dermatol Symp Proc (2006) 1.26
Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci U S A (2009) 1.23
Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood (2013) 1.22
Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J (2002) 1.22
Acid sphingomyelinase is a key regulator of cytotoxic granule secretion by primary T lymphocytes. Nat Immunol (2009) 1.20
Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism. J Clin Invest (2006) 1.20
Bax-induced cytochrome c release from mitochondria depends on alpha-helices-5 and -6. Biochem J (2004) 1.19
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med (2013) 1.19
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A (2008) 1.18
HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol (2003) 1.17
Crystal structure of the BEACH domain reveals an unusual fold and extensive association with a novel PH domain. EMBO J (2002) 1.17
Fusogenicity of membranes: the impact of acid sphingomyelinase on innate immune responses. Immunobiology (2007) 1.12
Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget (2012) 1.11
Looking beyond death: a morphogenetic role for the TNF signalling pathway. J Cell Sci (2009) 1.11
Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther (2010) 1.10
Blood-based gene expression signatures in non-small cell lung cancer. Clin Cancer Res (2011) 1.09
Retracted Silencing of B cell receptor signals in human naive B cells. J Exp Med (2002) 1.09
The complex role of B7 molecules in tumor immunology. Trends Mol Med (2008) 1.09
Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One (2012) 1.08
Acid sphingomyelinase is required for efficient phago-lysosomal fusion. Cell Microbiol (2008) 1.08
Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res (2011) 1.07
Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate (2007) 1.07
Serpin-6 expression protects embryonic stem cells from lysis by antigen-specific CTL. J Immunol (2007) 1.07
Severe impairment in early host defense against Listeria monocytogenes in mice deficient in acid sphingomyelinase. J Immunol (2003) 1.07
Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis. Cancer Res (2005) 1.06
Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". Mol Ther (2013) 1.05
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther (2010) 1.04
CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. Cancer Res (2007) 1.04
Loss of serum response factor in keratinocytes results in hyperproliferative skin disease in mice. J Clin Invest (2009) 1.03
Acid sphingomyelinase is indispensable for UV light-induced Bax conformational change at the mitochondrial membrane. J Biol Chem (2005) 1.03
T lymphoid differentiation in human bone marrow. Proc Natl Acad Sci U S A (2003) 1.03
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology (2012) 1.03
Effective proliferation of human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted by IL-2. J Immunol (2007) 1.02
Alpha11 beta1 integrin-dependent regulation of periodontal ligament function in the erupting mouse incisor. Mol Cell Biol (2007) 1.02
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology (2012) 1.01
Large scale multiplex PCR improves pathogen detection by DNA microarrays. BMC Microbiol (2009) 1.01
Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer (2011) 1.01
CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation. Mol Ther (2011) 1.00
TNF-induced target cell killing by CTL activated through cross-presentation. Cell Rep (2012) 0.99
Depletion of annexin A5, annexin A6, and collagen X causes no gross changes in matrix vesicle-mediated mineralization, but lack of collagen X affects hematopoiesis and the Th1/Th2 response. J Bone Miner Res (2012) 0.99
Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep (2013) 0.99
Induction of inflammatory cytokines by a keratin mutation and their repression by a small molecule in a mouse model for EBS. J Invest Dermatol (2007) 0.98
Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic E. coli O104:H4 from the 2011 German outbreak. BMC Microbiol (2012) 0.98
T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol (2007) 0.98
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol (2013) 0.98